Written by: Matthias Schuhmacher
For the first time, the Office of the United States Trade Representative (USTR) has added the European Union to its Special 301 Watch List.
According to the 2026 Special 301 Report, the USTR’s concerns center on the proposed EU General Pharmaceutical Legislation (GPL), the European Union’s approach to geographical indications (GIs), and the implementation of legislation affecting digital copyright.
The full report is available here.
At first glance, the decision may appear surprising. The European Union is generally regarded as maintaining one of the world’s most sophisticated intellectual property systems. Patent protection remains robust, trademark enforcement is well-established, and the Unified Patent Court (UPC) has significantly strengthened patent enforcement across much of Europe.
The USTR’s criticism is therefore not directed at Europe’s patent system or its ability to enforce intellectual property rights. Instead, the decision reflects a broader concern regarding the direction of European innovation policy, particularly in the life sciences sector.
The Real Debate Is Not About Patents
Historically, the USTR’s Special 301 process focused primarily on jurisdictions with inadequate intellectual property protection, weak enforcement mechanisms, widespread counterfeiting, or systemic piracy concerns.
The inclusion of the European Union represents something fundamentally different.
There is no question that intellectual property rights can be obtained and enforced in Europe. The concern expressed by the USTR is not that Europe lacks intellectual property protection. Rather, the concern is that certain regulatory initiatives may reduce the incentives that drive innovation and investment.
The debate has therefore shifted from traditional intellectual property law toward a broader discussion concerning industrial policy, economic competitiveness, and innovation incentives. In other words, the relevant question is no longer whether intellectual property rights exist. The question is whether the overall regulatory environment sufficiently rewards innovation.
Why the Pharmaceutical Reform Matters
The proposed EU General Pharmaceutical Legislation seeks to modernize the European pharmaceutical framework and address a number of policy objectives, including improving access to medicines, increasing availability throughout the European Union, and supporting the sustainability of healthcare systems.
These objectives are legitimate and widely supported.
However, critics have expressed concern that certain aspects of the reform may reduce the commercial incentives associated with developing innovative medicines. In particular, concerns have been raised regarding the structure and duration of regulatory exclusivities and the increasing linkage of exclusivity periods to broader policy objectives.
The USTR’s inclusion of the European Union on the Watch List reflects the view that reducing regulatory protections may weaken incentives for pharmaceutical innovation.
Whether one agrees with that assessment is ultimately a policy question. Nevertheless, the decision highlights a growing divergence between U.S. and European approaches to pharmaceutical innovation.
While European policymakers increasingly focus on affordability, accessibility, and healthcare sustainability, U.S. policymakers continue to emphasize the importance of maintaining strong incentives for innovation and investment.
A Question of Global Competitiveness
The most significant aspect of the USTR’s decision may be its potential implications to Europe’s attractiveness as a destination for pharmaceutical innovation.
Pharmaceutical companies make investment decisions over decades, not years. The development of a new therapy frequently requires billions of dollars in research and development expenditure and substantial regulatory risk.
As a result, companies carefully evaluate the legal and regulatory environment in which they invest. Patent protection is only one factor. Regulatory exclusivities, data protection periods, pricing frameworks, reimbursement systems, approval timelines, and overall regulatory predictability are equally important.
The USTR’s decision can therefore be understood as a signal that the United States believes certain European policy choices risk making Europe a less attractive jurisdiction for pharmaceutical innovation and investment.
Whether that concern ultimately proves justified remains to be seen. Europe continues to benefit from world-class universities, highly skilled scientific talent, sophisticated healthcare systems, and strong intellectual property protection.
Nevertheless, the question raised by the USTR deserves attention: if innovative companies perceive that the rewards for innovation are diminishing, where will they choose to deploy their next generation of research and development resources?
The answer to that question may have significant implications for future investment flows, research activity, and long-term competitiveness.
Geographical Indications and Digital Copyright
The USTR also identified concerns regarding the European Union’s approach to geographical indications and certain aspects of digital copyright legislation.
. The European Union generally favors strong protection of regional product names, whereas the United States has traditionally argued that many such names have become generic outside Europe and should remain available for use by producers in other jurisdictions.
Similarly, disagreements regarding digital copyright legislation reflect broader differences in regulatory philosophy concerning the balance between intellectual property protection, competition, and digital market regulation.
While these issues remain important, they are unlikely to have the same strategic significance as the ongoing debate surrounding pharmaceutical innovation and investment.
Beyond Intellectual Property
Perhaps the most important takeaway from the USTR’s decision is that intellectual property policy is increasingly becoming innovation policy.
Questions concerning exclusivities, regulatory incentives, market access, and commercialization are no longer confined to intellectual property lawyers. They have become central issues of industrial policy, healthcare policy, economic competitiveness, and international trade.
The inclusion of the European Union on the Special 301 Watch List illustrates this shift.
The dispute is not about whether innovation should be rewarded. Both the United States and the European Union recognize the importance of innovation. The disagreement concerns how innovation should be rewarded and whether current policy choices strike the appropriate balance between encouraging investment and achieving broader public policy objectives.
Looking Ahead
The addition of the European Union to the U.S. Special 301 Watch List does not suggest that Europe lacks a sophisticated intellectual property system. Nor does it indicate that European patents have become weaker or less enforceable.
Rather, it reflects a growing transatlantic disagreement regarding the conditions necessary to sustain innovation.
For companies operating in the pharmaceutical, biotechnology, and medical technology sectors, the development warrants close attention. The outcome of this debate may influence future legislative reforms, trade negotiations, investment decisions, and ultimately the geographic distribution of pharmaceutical research and development.
The question raised by the USTR is therefore not whether Europe protects intellectual property -the question is whether Europe will remain one of the world’s most attractive places to invest in pharmaceutical innovation.
